Levacetilmetadol [Inn-Spanish]
Brand names,
Levacetilmetadol [Inn-Spanish]
Analogs
Levacetilmetadol [Inn-Spanish]
Brand Names Mixture
Levacetilmetadol [Inn-Spanish]
Chemical_Formula
C23H31NO2
Levacetilmetadol [Inn-Spanish]
RX_link
http://www.rxlist.com/cgi/generic2/levomethadyl.htm
Levacetilmetadol [Inn-Spanish]
fda sheet
Levacetilmetadol [Inn-Spanish]
msds (material safety sheet)
Levacetilmetadol [Inn-Spanish]
Synthesis Reference
No information avaliable
Levacetilmetadol [Inn-Spanish]
Molecular Weight
353.498 g/mol
Levacetilmetadol [Inn-Spanish]
Melting Point
No information avaliable
Levacetilmetadol [Inn-Spanish]
H2O Solubility
>15 mg/mL
Levacetilmetadol [Inn-Spanish]
State
Solid
Levacetilmetadol [Inn-Spanish]
LogP
6.139
Levacetilmetadol [Inn-Spanish]
Dosage Forms
Solution
Levacetilmetadol [Inn-Spanish]
Indication
LAAM is indicated for the treatment and management of opiate dependence. It is sometimes used to treat severe pain in terminal patients.
Levacetilmetadol [Inn-Spanish]
Pharmacology
LAAM is a synthetic synthetic opioid analgesic with multiple actions quantitatively similar to those as morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, LAAM is more active and more toxic than morphine. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The LAAM abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.
Levacetilmetadol [Inn-Spanish]
Absorption
LAAM is rapidly absorbed from an oral solution.
Levacetilmetadol [Inn-Spanish]
side effects and Toxicity
Signs of overdose include apnea, circulatory collapse, pulmonary edema, cardiac arrest, and death.
Levacetilmetadol [Inn-Spanish]
Patient Information
No information avaliable
Levacetilmetadol [Inn-Spanish]
Organisms Affected
Humans and other mammals